18 October 2022
Absence of biomarker profiles typical of Alzheimer’s disease
A new study from Karolinska Institutet and the Karolinska University Hospital indicates that only a rather small proportion of individuals attending a specialized memory clinic have an Alzheimer’s disease-type biomarker profile and could be considered eligible for novel disease-modifying treatments targeting amyloid. The study, published online on September 21, 2022, in Neurology®, the medical journal of the American Academy of Neurology, was conducted as part of the strategic research collaboration between Karolinska Institutet and Janssen Pharmaceutica NV, part of the Janssen Pharmaceutical Companies of Johnson & Johnson.
Link to publication:
Share the article
Learn how you can support our work
We are a Swedish non-profit foundation that is dependent on external donations and grants. There are several ways you can support the work of the FINGERS Brain Health Institute as an individual, foundation, corporation, or other organization.